Global Bone Resorption Inhibitors Market, By Indication (Osteoporosis, Paget's Disease of The Bone and Malignant Hypercalcemia, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Bone Resorption Inhibitors Market Analysis and Size
The global bone resorption inhibitors market is expected to witness significant growth during the forecast period. The growth of bone resorption inhibitors market enhanced by the growing cases of osteoporosis, Paget's disease of the bone and malignant hypercalcemia and ongoing research and development. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global bone resorption inhibitors market in the forecast period 2022-2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Osteoporosis is a type of skeletal disorder that predominantly affect postmenopausal women. With regards to the consequences, the bone loses density and the stability of the inner spongy structure declines until the bone can no longer withstand and the external stresses and strains the bone then brakes. Bone resorption inhibitors inactivate the mineralization or resorption of the bone by hindering the activity of osteoclasts. It is becoming of great importance to the healthcare sector and is expected to expand in the coming times.
Bone Resorption Inhibitors Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Indication (Osteoporosis, Paget's Disease of The Bone and Malignant Hypercalcemia, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), Mylan N.V. (U.S.), Novartis AG (Switzerland), Hikma Pharmaceuticals plc (U.K.), Aurobindo Pharma (India), Melinta Therapeutics, Inc (U.S.), Janssen Global Services, LLC (U.S.), Bristol-Myers Squibb Company (U.S.), GSK plc. (U.K.), Bayer AG (Germany), Teva Pharmaceuticals Industries Ltd. (Israel), Lilly (U.S.), AstraZeneca (U.K.), Breckenridge Pharmaceutical, Inc. (Germany)
|
|
Market Opportunities
|
|
Global Bone Resorption Inhibitors Market Dynamics
Drivers
- Increased Incidence of Osteoporosis
Increasing prevalence of osteoporosis are expected to boost the market growth over the forecast period 2022-2029. For instance, according to the National Osteoporosis Foundation (NOF) reports, approximately 54 million people in America have osteoporosis. The rise in the osteoporosis disease pose a huge demand for the osteoporosis drugs. Thus, it boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Elderly Population
Rising number of elderly populations are suffering from osteoporosis disease. There is very huge growth in osteoporosis disease in the geriatric population. For instance, according to The National Osteoporosis Foundation (NOF) reports, approximately one out of two women and one out of four men aged 50 and above is suffering from a bone break due to osteoporosis. This creates an opportunity for the market expansion.
- Increasing Demand for Retail Pharmacies
The rise in the number of bone resorption inhibitors delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Risk of Side-Effects
The varied side-effects that are associated with bone resorption inhibitors could curb the growth of the global bone resorption inhibitors market over a forecast period. Side-effects such as dyspepsia and headache, and to a lesser extent, myalgia, low-back pain, flushing, and rhinitis are visible with the use of bone resorption inhibitors.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global bone resorption inhibitors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global bone resorption inhibitors contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Bone Resorption Inhibitors Market
COVID-19 has left a global public health crisis that has impacted every business, and its long-term consequences are expected to have a major influence on industry growth during the forecast period. Shift of healthcare infrastructure toward managing COVID-19 has led to drug launch withdrawals and delays in clinical trials.
In the post-pandemic era, changes are witnessed in use of different inhibitors. Multiple socioeconomic stressors have also enhanced the demand for these drugs. Thus, this will significantly impact the bone resorption inhibitors market.
Global Bone Resorption Inhibitors Market Scope
The global bone resorption inhibitors market is segmented on the basis of indication, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Indication
- Osteoporosis
- Paget's Disease of The Bone and Malignant Hypercalcemia
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Bone Resorption Inhibitors Market Regional Analysis/Insights
The global bone resorption inhibitors market is analysed and market size insights and trends are provided by indication, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global bone resorption inhibitors market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a positive growth for global bone resorption inhibitors market throughout the forecasted period due to the developing healthcare facilities and rise in government initiatives and awareness.
North America dominates the market due to the global leaders in research and development activities, advances in the treatment and increase prevalence of osteoporosis.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Bone Resorption Inhibitors Market Share Analysis
The global bone resorption inhibitors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global bone resorption inhibitors market
Key players operating in the global bone resorption inhibitors market include:
- Pfizer Inc (U.S.)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Hikma Pharmaceuticals plc (U.K.)
- Aurobindo Pharma (India)
- Melinta Therapeutics, Inc (U.S.)
- Janssen Global Services, LLC (U.S.)
- Bristol-Myers Squibb Company (U.S.)
- GSK plc. (U.K.)
- Bayer AG (Germany)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- Lilly (U.S.)
- AstraZeneca (U.K.)
- Breckenridge Pharmaceutical, Inc. (Germany)
SKU-